This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Sep 22;128(12):1540-1.

doi: 10.1182/blood-2016-08-730374.

BV for HL: can the responses last?

Affiliations

PMID: 27658697
DOI: 10.1182/blood-2016-08-730374

Free article

Comment

BV for HL: can the responses last?

Brad S Kahl. Blood. 2016.

Free article

. 2016 Sep 22;128(12):1540-1.

doi: 10.1182/blood-2016-08-730374.

Author

Affiliation

¹ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE.

PMID: 27658697
DOI: 10.1182/blood-2016-08-730374

No abstract available

PubMed Disclaimer

Comment on

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Chen R, et al. Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18. Blood. 2016. PMID: 27432875 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations